Compare CTMX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTMX | NDMO |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 622.4M |
| IPO Year | 2015 | N/A |
| Metric | CTMX | NDMO |
|---|---|---|
| Price | $3.89 | $10.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 218.6K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.75% |
| EPS Growth | ★ 50.22 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $113,631,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $8.99 |
| 52 Week High | $4.62 | $11.24 |
| Indicator | CTMX | NDMO |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 36.17 |
| Support Level | $3.66 | $10.22 |
| Resistance Level | $4.20 | $10.66 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 43.84 | 15.91 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.